Fluticasone furoate/vilanterol
Lua error in Module:Infobox at line 314: malformed pattern (missing ']').
Fluticasone furoate/vilanterol (trade names Breo Ellipta and Relvar Ellipta) is a combination drug for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, an ultra-long-acting β2 agonist (ultra-LABA).
In 2013, the drug was approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema,[1] and the European Medicines Agency approved it as a second-line therapy for the treatment of COPD and asthma.[2]
There are; however, concerns that LABAs such as vilanterol increase the risk of deaths due to asthma.[1]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." />External links
- Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) Official Site
- Breo Ellipta (fluticasone furoate and vilanterol) Inhalation Powder, for Oral Inhalation. U.S. Full Prescribing Information
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
- Pages with reference errors
- Drugs that are a combination of chemicals
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Combination drugs
- Drugs acting on the respiratory system
- Long-acting beta2-adrenergic agonists
- Respiratory system drug stubs
